Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
OLANZAPINE - A NEW ANTIPSYCHOTIC AGENT WITH EFFICACY IN THE MANAGEMENT OF SCHIZOPHRENIA
Autore:
KANDO JC; SHEPSKI JC; SATTERLEE W; PATEL JK; REAMS SG; GREEN AI;
Indirizzi:
MASSACHUSETTS MENTAL HLTH CTR,COMMONWEALTH RES CTR,74 FENWOOD RD BOSTON MA 02115 MEDMANAGEMENT,CLIN PHARM SERV,MASSACHUSETTS PROJECT TEWKSBURY MA 00000 HARVARD UNIV,SCH MED CAMBRIDGE MA 02138 LILLY RES LABS,CLIN RES INDIANAPOLIS IN 00000 MASSACHUSETTS MENTAL HLTH CTR,COMMONWEALTH RES & EVALUAT UNIT BOSTON MA 02115 ELI LILLY & CO,LILLY RES LABS INDIANAPOLIS IN 46285
Titolo Testata:
The Annals of pharmacotherapy
fascicolo: 11, volume: 31, anno: 1997,
pagine: 1325 - 1334
SICI:
1060-0280(1997)31:11<1325:O-ANAA>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC-RESISTANT SCHIZOPHRENIA; A10 DOPAMINE NEURONS; DOUBLE-BLIND; CLOZAPINE TREATMENT; TARDIVE-DYSKINESIA; RISPERIDONE; HALOPERIDOL; PLACEBO; DYSFUNCTION; ANTAGONISM;
Keywords:
OLANZAPINE; SCHIZOPHRENIA;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
59
Recensione:
Indirizzi per estratti:
Citazione:
J.C. Kando et al., "OLANZAPINE - A NEW ANTIPSYCHOTIC AGENT WITH EFFICACY IN THE MANAGEMENT OF SCHIZOPHRENIA", The Annals of pharmacotherapy, 31(11), 1997, pp. 1325-1334

Abstract

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of olanzapine as a treatment for schizophrenia and to determine the advantages and disadvantages of this atypical antipsychotic agent compared with currently marketed agents. DATA SOURCES: A MEDLINE computer literature search was conducted to retrieve all English-language studies and review articles involving olanzapine published as of October 1, 1996. The manufacturer of the drug, Eli Lilly and Company, provided the clinical investigator's brochure and abstractsof unpublished Phase III clinical trials. STUDY SELECTION: Animal studies evaluating the pharmacology of olanzapine were evaluated, as wereall open-label and double-blind studies involving the evaluation of olanzapine for the treatment of patients with schizophrenia. DATA EXTRACTION: All available clinical studies were reviewed and the interpretation of data for each study was influenced by the size of the study sample, the nature of the inclusion and exclusion criteria, and the dataanalysis techniques used. DATA SYNTHESIS: Olanzapine is a thienobenzodiazepine analog with an in vitro receptor affinity profile similar tothat of clozapine, Olanzapine exhibits linear kinetics over the dosage range studied and is extensively metabolized in humans. Clinical evaluations to date have shown olanzapine to be at least as efficacious as typical antipsychotic agents in the treatment of the acute phase of schizophrenia. The drug was well tolerated, with significantly fewer extrapyramidal adverse effects than haloperidol. Current data suggest that olanzapine may be more effective than haloperidol for the treatment of negative symptoms; moreover, preliminary data suggest that fewer relapses occur over the course of treatment in patients treated with olanzapine compared with those taking haloperidol. CONCLUSIONS: The exact place of olanzapine in the therapy of psychotic patients remains unclear, as more data are needed to evaluate the long-term efficacy of this agent, its impact on negative symptoms, and its potential use in patients resistant to the standard agents. Despite limitations in the current database, olanzapine is a promising treatment option for patients with schizophrenia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 01:38:59